Sangamo Therapeutics Inc
$ 0.28
7.54%
15 Apr - close price
- Market Cap 105,971,000 USD
- Current Price $ 0.28
- High / Low $ 0.29 / 0.25
- Stock P/E N/A
- Book Value -0.04
- EPS -0.44
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.84 %
- ROE -28.92 %
- 52 Week High 0.84
- 52 Week Low 0.21
About
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
Analyst Target Price
$3.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-01 | 2024-08-06 | 2024-05-09 | 2024-03-13 | 2023-11-01 | 2023-08-08 | 2023-04-26 |
| Reported EPS | -0.0722 | -0.11 | -0.08 | -0.14 | -0.11 | 0.0438 | -0.18 | -0.27 | -0.34 | -0.59 | -0.66 | 0.12 |
| Estimated EPS | -0.0132 | 0.0002 | -0.02 | -0.13 | -0.0909 | -0.03 | -0.15 | -0.21 | -0.26 | -0.32 | -0.34 | -0.33 |
| Surprise | -0.059 | -0.1102 | -0.06 | -0.01 | -0.0191 | 0.0738 | -0.03 | -0.06 | -0.08 | -0.27 | -0.32 | 0.45 |
| Surprise Percentage | -446.9697% | -55100% | -300% | -7.6923% | -21.0121% | 246% | -20% | -28.5714% | -30.7692% | -84.375% | -94.1176% | 136.3636% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGMO
2026-04-09 18:09:16
The Fabry Disease market is projected for significant growth by 2034, driven by advancements in gene therapy and a robust pipeline from companies like Sangamo, Sanofi, and Amicus. The market, valued at approximately USD 1,700 million in 2024, is expected to expand due to increasing disease prevalence and awareness. Key developments include Sangamo Therapeutics' investigational gene therapy ST-920, which is pursuing accelerated FDA approval, and the United States holding the largest market share for Fabry Disease therapeutics.
2026-04-07 18:11:20
HC Wainwright has revised its FY2026 earnings per share estimate for Sangamo Therapeutics (NASDAQ:SGMO) to ($0.17) from ($0.10) but maintains a "Buy" rating and a $10.00 price target. The biopharmaceutical company recently missed its Q4 2026 earnings, reporting ($0.11) EPS against an expected $0.01, with revenues also significantly below estimates. Despite a consensus "Hold" rating from other analysts and an average target price of $5.50, the stock is currently trading around $0.26.
2026-04-04 19:39:24
Sangamo Therapeutics Inc. announced positive top-line results from the STAR study in Fabry disease, initiating their first wholly-owned Biologics License Agreement (BLA) submission to the FDA. The company also secured a third neurology capsid license with Eli Lilly and received Fast Track designation for SC503, an investigational treatment for small fiber neuropathy. Despite these advancements, Sangamo faces challenges including regulatory and market uncertainty, delays in CMC activities for BLA submission, limited cash resources, and the ongoing search for a commercial partner for its Fabry program.
2026-04-03 20:39:48
Sangamo Therapeutics CEO Sandy Macrae has been granted 2.5 million stock options with an exercise price of $0.2601 per share, expiring in March 2036. The options vest over approximately three years, with one-quarter vesting on the first anniversary and the remainder in monthly installments thereafter, contingent on continuous service. This grant aligns Macrae's incentives with the company's long-term stock performance without immediate share issuance or open-market transactions.
2026-04-01 21:10:35
Sangamo Therapeutics' SVP and Chief Legal Officer, Scott B. Willoughby, was granted 800,000 stock options with an exercise price of $0.2601 per share, expiring on March 31, 2036. These options are part of his compensation, with a quarter vesting after one year and the remainder vesting monthly over 24 installments, contingent on his continued service. This transaction is a compensation award and not an open-market purchase or sale.
2026-03-31 08:40:38
Sangamo Therapeutics Inc. reported a Q4 loss of $37.4 million, or 11 cents per share, with adjusted losses at 7 cents per share. The company's revenue for the quarter was $14.2 million. For the entire year, Sangamo recorded a loss of $122.9 million on $39.6 million in revenue.
